19:11 , May 8, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Diabetes Cell culture and mouse studies identified an aminothioimidazole-based GPBAR1 agonist that could help treat insulin resistance. Chemical synthesis and testing of aminothioimidazole analogs in cell-based assays yielded a compound that agonized human and mouse...
07:00 , Mar 12, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: G protein-coupled bile acid receptor 1 (GPBAR1; TGR5); glucagon-like peptide 1 (GLP-1)

Endocrine/metabolic disease INDICATION: Diabetes Mouse studies have identified a 4-phenoxynicotinamide-based TGR5 agonist that could help treat diabetes without the systemic side-effects of existing TGR5 ligands. Synthesis and in vitro testing of 4-phenoxynicotinamide analogs identified a lead compound...
08:00 , Nov 18, 2013 |  BioCentury  |  Strategy

BMS reaches pivot point

Bristol-Myers Squibb Co. isn't talking publicly about narrowing its focus by dropping discovery in several crowded and/or particularly difficult disease areas while doubling down on others like cancer immunotherapy. Nevertheless, the decision looks to be...
07:00 , Mar 21, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Hepatic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Hepatic disease Liver disease Farnesoid X receptor (FXR; NR1H4); G protein-coupled bile acid...
07:00 , Oct 15, 2012 |  BioCentury  |  Product Development

Gut instinct

Ardelyx Inc. took its gut-specific small molecule approach from concept to Phase II testing in under four years and now has scored a partnership with AstraZeneca plc as the pharma adds diabetic complications as a...
07:00 , Jul 9, 2012 |  BioCentury  |  Strategy

Triple play in diabetes

The addition of Amylin Pharmaceuticals Inc.'s glucagon-like peptide 1 franchise will give partners Bristol-Myers Squibb Co. and AstraZeneca plc three modern mechanisms in their commercial diabetes portfolio and five in the pipeline - more than...
08:00 , Jan 5, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Atherosclerosis G protein-coupled bile acid receptor 1 (GPBAR1; TGR5) Mouse studies suggest agonizing TGR5 could help...
07:00 , Aug 15, 2011 |  BC Week In Review  |  Company News

Intercept Pharmaceuticals, Servier deal

The companies partnered to discover and develop treatments for Type II diabetes and other metabolic diseases from Intercept's G protein-coupled bile acid receptor 1 ( GPBAR1; TGR5) agonist program. The partners will use...
00:08 , Aug 10, 2011 |  BC Extra  |  Company News

Intercept partners TGR5 program with Servier

Intercept Pharmaceuticals Inc. (New York, N.Y.) partnered with Servier (Neuilly-sur-Seine, France) to discover and develop treatments for Type II diabetes and other metabolic diseases from Intercept's G protein-coupled bile acid receptor 1 ( GPBAR1; TGR5)...
07:00 , Jul 18, 2011 |  BC Week In Review  |  Company News

Exelixis, Bristol-Myers deal

Exelixis said Bristol-Myers will return all rights under a 2008 deal to XL281, effective Oct. 8. According to Exelixis, Bristol-Myers made the decision based on the pharma's review of XL281 in its "overall research and...